Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic Malignancies
Age 18-80 years, regardless of gender;
Histopathologically confirmed or clinically diagnosed hepatic malignancies, including primary liver cancer and metastatic liver cancer;
Presence of an image-evaluable target lesion for ablation, with the maximum diameter of the target lesion being 3-5 cm;
Patient is intolerant to or refuses surgical resection;
Liver function classified as Child-Pugh C, unimprovable with hepatoprotective therapy;
Massive or diffuse hepatocellular carcinoma;
Presence of vascular tumor thrombus or invasion of adjacent organs;
History of esophageal (gastric fundus) variceal rupture and bleeding within 1 month prior to treatment;
Single group
Multimodal Tumor Thermal Ablation
DeviceMultimodal Tumor Thermal Ablation
Ablation efficacy rate at 1 month postoperatively
Ablation efficacy rate at 1 month postoperatively
Changes in the Peripheral Blood Immune Microenvironment Before and After Treatment
Changes in the Peripheral Blood Immune Microenvironment Before and After Treatment
Adverse events and serious adverse events
Adverse events and serious adverse events
Click on the lead sponsor to view all of their trials.
